Alnylam Pharmaceuticals | Frais De Vente Et D'Administration



Selling And Administration Expenses Changement Date
Acadia Pharmaceuticals USD 123.66M 2.71M 2025-06
Agios Pharmaceuticals USD 45.87M 4.34M 2025-06
Alnylam Pharmaceuticals USD 323.31M 83.36M 2025-06
Amgen USD 1.69B 4M 2025-06
Arrowhead Research USD 30.95M 3.06M 2025-06
BioMarin Pharmaceutical USD 232.28M 26.16M 2025-06
Incyte USD 331.02M 5.33M 2025-06
Ionis Pharmaceuticals USD 90.6M 14.6M 2025-06
Moderna USD 230M 18M 2025-06
Neurocrine Biosciences USD 286.3M 9.8M 2025-06
Novartis USD 3.5B 368M 2024-12
PTC Therapeutics USD 85.26M 76.66M 2025-06
Regeneron Pharmaceuticals USD 634.2M 1.2M 2025-06
Sanofi EUR 1.24B 1.44B 2024-12
Sarepta Therapeutics USD 69.89M 63.74M 2025-06
Takeda JPY 255.89B 39.98B 2025-06
Tectonic Therapeutic USD 4.84M 469K 2024-12
Ultragenyx Pharmaceutical USD 86.65M 1.15M 2025-06
Vertex Pharmaceuticals USD 424.6M 28.2M 2025-06
Xencor USD 15.11M 2.22M 2025-06


Alnylam Pharmaceuticals Frais De Vente Et D'Administration - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Aug 2025.